The association of insulin-dependent diabetes mellitus (IDDM) with certain HLA alleles is well documented in pediatric patients. Whether a similar association is found in adult-on-set IDDM is not clear, although the disease occurs after the age of 20 in 50% of cases. HLA class II DRB1, DQA1, and DQB1 alleles were studied in 402 type I diabetics and 405 healthy controls (all Caucasian) using oligonucleotide typing after gene amplification. Alleles DRB1*03, DRB1*04, DQB1*0201, DQB1*0302, DQA1*0301, and DQA1*0501 were indeed enriched in diabetics and the highest relative risk was observed in patients carrying both the DRB1*03-DQB1*0201 and the DRB1*0402 or DRB1*0405-DQB1*0302 haplotypes. However none of these alleles, or specific residues, could alone account for the susceptibility to IDDM. Furthermore, there were major differences in HLA class II gene profiles according to the age of onset. Patients with onset after 15 yr (n = 290) showed a significantly higher percentage of non-DR3/non-DR4 genotypes than those with childhood onset (n = 112) and a lower percentage of DR3/4 genotypes. These non-DR3/non-DR4 patients, although presenting clinically as IDDM type 1 patients, showed a lower frequency of islet cell antibodies at diagnosis and a significantly milder initial insulin deficiency. These subjects probably represent a particular subset of IDDM patients in whom frequency increases with age. The data confirm the genetic heterogeneity of IDDM and call […] 
Introduction
Convergent arguments indicate that insulin-dependent diabetes mellitus (IDDM)' is secondary to the autoimmune de- 1 . Abbreviations used in this paper: Cs-A, cyclosporin A; HbA IC, glycosylated hemoglobin; IAA, insulin autoantibodies; ICA, islet cell antibodies; IDDM, insulin-dependent diabetes mellitus; NIDDM, non-insulin-dependent diabetes mellitus; PCR, polymerase chain reaction; RR, relative risk; SSO, sequence-specific oligonucleotides; TMAC, tetramethylammonium chloride. struction of ,3 cells in the pancreatic islets of Langerhans (1) .
IDDM has long been known to be associated with particular HLA alleles and there is substantial evidence from family studies that the major loci that confer disease susceptibility map to the class II region of the MHC (2) . Among Caucasians, the disease is positively associated with DR3 and DR4 and negatively associated with DR2 (3) (4) (5) . Recently, on the basis of restriction length fragment polymorphism (RFLP) and oligonucleotide typing, the notion has emerged that IDDM susceptibility or resistance is preferentially associated with a limited number of alleles of the HLA-DQB locus (6) (7) (8) (9) (10) . Susceptibility has also been assigned to DQB1 alleles encoding amino acids other than aspartic acid (Asp) at position 57 of the DQI3 chain (11 -14) . However, an exclusive role of DQB genes (particularly the Asp 57 residue) is unlikely given the growing evidence that a single allele cannot account for MHC-associated genetic susceptibility. To take account of a possible genetic heterogeneity, accurate assessment ofthe HLA-IDDM association should involve extensive definition of class II alleles and integrate this with clinical and immunological parameters in a large series of patients. In most studies, a limited number of alleles has been tested and patients have not been investigated beyond the diagnosis of IDDM. Furthermore, most reported data have been obtained in pediatric patients, although IDDM occurs over the age of 20 yr in one half of cases (15) .
Class II oligotyping is a rapid and efficient tool that can be used for large-scale screening (16) . It permits exquisite definition of HLA polymorphism and provides an important means of recognizing genes associated with disease susceptibility or resistance. Taking advantage of our access to large groups of adult-and childhood-onset IDDM patients with well-defined clinical, biological, and immunological status, we assessed the role ofclass II alleles in IDDM predisposition and presentation. Using DNA amplification followed by hybridization with sequence-specific oligonucleotides (SSO), we studied 290 adultonset IDDM patients, 112 DNA extraction and polymerase chain reaction (PCR). DNA was extracted from 2 ml of fresh whole blood using short proteinase K digestion of detergent-treated cells (23) . The second exons encoding the polymorphic outer domains of the HLA DRfl1, DQct1, and DQflI chains were separately amplified following the PCR procedure, using specific DNA flanking primers (24, 25 Oligonucleotide probes. 14 SSOs were used for DRB1 generic typing, 8 for DR4 subtyping, 12 for DQB, and 8 for DQA typing. These probes were synthesized in our laboratory using the sequences reported by Tiercy et al. (25, 26) .
Statistical analysis. The odds ratio was calculated according to Woolf's formula and, by convention, expressed as a relative risk (RR). Haldane's modification of the formula was used when one element of the equation was zero. The statistical significance of the difference of RR from unity was tested by chi-square analysis with one degree of freedom using the formula: x2 = (1 IV) (loge RRP)2, where V is the sampling variance (27) . The level of significance was set to 0.05. PC indicates a P value corrected by use of Bonferonni inequality method, by multiplying P by the number ofalleles compared. Gene frequencies (g) were calculated from the observed allele frequencies (f) using the formula: g = 1 -V (I -f) Different groups of IDDM patients were compared according to various clinical or biological parameters using chi-square analysis with
Yates' correction when appropriate.
Results
Positive associations ofclass II alleles with IDDM Distribution ofDRB, DQB, and DQA alleles. The distribution of DRB 1, DQA 1, and DQB 1 alleles among the 405 healthy controls was comparable to that in previous reports and closely matched with the expected frequencies in Caucasoid individuals (Table II) , indicating that our population was in HardyWeinberg equilibrium. When all the IDDM patients (children and adults) were considered as a whole, the well-known positive association of DR3 and DR4 with IDDM in Caucasians was confirmed: 86.1% of the patients were DR3 and/or DR4 compared with only 44.1% of the healthy controls. However, when the pediatric and adult patients were compared, we found a significant difference in some class II risk alleles according to age at clinical onset. The HLA DR3 allele was present in 52% of the adults compared with only 26% in the controls (P < 0.005) and 69% in childhood IDDM. The prevalence ofthe HLA DR4 allele was 48% in the adult patients (controls: 20%, P < 0.005) and 66% in the pediatric patients (Table II, top). Similar differences were found between the adult and child patients with regard to DQB1 *0201 and 0302 alleles (Table II, middle) as well as DQA1 *0301 (Table II, bottom ). An age gradient was established, indicating that the DR3/4 frequency significantly decreased with the age of IDDM onset ( Fig. 1) , whereas the proportion of non-DR3/non-DR4 subjects increased. Among the children aged < 15 yr at onset, 37.5% were DR3/4 heterozygotes (RR = 23.4) and 97.3% possessed the DR3 and/or DR4 alleles. These high frequencies are similar to those usually reported in the literature. Conversely, only 17.9% of the adult-onset diabetics were DR3/4 heterozygotes (RR = 8.5), and only 81.7% possessed the DR3 and/or DR4 alleles (PC < 0.001 relative to the children). Patients >30 yr at the time of onset were non-DR3/non-DR4 in 25.8% of cases (Table III) .
The DR3-associated susceptibility was significant in both the adult (RR = 2.97) and pediatric (RR = 6.11) patients. It was abolished in heterozygous patients when combined with DR2 (2.1% of adults, 1 came the DR4 susceptibility effect (DR2 /4: 3.4% of adult patients, 3.3% of pediatric patients, and 2.7% of controls). It is noteworthy that the frequency of DR4 homozygous patients was not significantly different from that in the healthy control group (6.2% in adult diabetics, 7.1% in children, and 1.2% in controls, NS). It has been reported that the DR 1/4 heterozygous genotype is significantly increased in IDDM patients, although DR4 was linked to the DQB 1 *0301 protective allele (28) . This was not observed in our two patient groups (4.5% in adults and 4.4% in children vs. 3.7% in controls), in which the DRl /4 combination was neutral.
The distribution of DRB 1 alleles in non-DR3 / non-DR4 IDDM patients strictly paralleled that in normal controls. Thus, no significant increase of any particular DRB 1 allele was observed. DQB 1*0201 was significantly associated with IDDM in both groups of patients. This susceptibility was abolished when DQB 1 *0201 was paired with the protective DQB 1 *0602 allele Fig. 1 ). Even the combination to the protective DQB 1 *0602 allele did not fully abolish the DQB 1 *0302-associated susceptibility (1.1% of adult diabetics and 1.4% of children vs. 0% of controls), indicating that the influence of DQB1 *0302 could be dominant.
DR4 subtypes associated with IDDM. The above results of DR4 typing were obtained using a probe that hybridizes with a sequence common to all DR4 subtypes (0401-0408). However, characterization of DR4 subtypes using specific probes in both adult-and childhood-onset patients revealed that the DRB1 *0402 (Dw10) and 0405 (Dw15) alleles were strongly associated with the disease (RR = 15.4 and 18.1, respectively, Pc < 0.05), whereas DRB1*0401 (Dw4) was neutral (RR = 0.9) and DRB 1 *0404 (Dw 14) had a significant protective effect (RR = 0.26) (Table IV) . Although differences between adult and pediatric groups were not significant, a tendency for an increase of DRB1 *0402 allele in adults (22.9 vs. 14% in children and 5.6% in controls) and a decrease of DRB 1 *0401 (41.6% in adults vs. 50.9% in children and 50.4% in controls) was observed. This observation differs from previous reports suggesting that DRB 1*0401 is the most frequent allele in DR4-positive IDDM patients (5, 29) . The results concerning DRB1 *0405 were particularly interesting: 19.2% of the DR4-positive patients (both in adult and child diabetics) expressed this allele, which is not usually found in Caucasian populations. When the frequencies of DRB 1 *0401, 0402, and 0405 in all IDDM patients were combined, the RR reached statistical significance (RR = 5.5). Taken together, DRB1 *0402 and 0405 gave a highly significant risk of 27.9. Two main haplotypes have been identified among DR2 subjects on the basis of sequence polymorphism: DRB1 * 1501 (Dw2)-DRB5 *0101-DQB1 *0602 and DRB1 *1601 (Dw2l-AZH)-DRB5*0201-DQB1*0502. The former (Dw2) has been reported to be protective whereas the latter (Dw2 I-AZH) is usually associated with IDDM (5, 31, 32) . Results obtained in this study confirm the protective role of DR15 (deduced haplotype from DQB 1 *0602), although less strikingly than in the diabetic children: 4.8% of the adult IDDM patients were DR2-DQB1 *0602 compared with 18.6% of the normal controls (RR = 0.22) and 2.8% of the diabetic children (RR = 0.13) . The significant protective effect of DQB 1 *0602 was observed in all the heterozygous combinations, except with DQB 1 *0302. Surprisingly, the DR 16 (Dw2 I-AZH )-DQB 1 *0502 haplotype was not significantly more frequent in our adult patients. Thus, in the DR2 subgroup, only 38.5% ofthe adult-onset IDDM patients were DR16-DQB1 *0502 versus 33.6% of the normal controls (NS) and 77.8% of the diabetic children. This observation contrasts with previous reports showing a strong association ofthis haplotype (rarely found in the normal population) with the disease.
Two of the DR2 adult IDDM patients had a DQBl gene different from those usually found in healthy DR2 individuals. Instead of DQB1 *0602 or 0502, the DQB1 *0402 allele was present in both cases, in association with the DQA1 *0401 allele. The occurrence of such recombinant haplotypes between DQA and DR subregions should be confirmed by family typing, although it has recently been found in two other DR2 IDDM patients (33). No recombinant haplotype was observed in our DR2 controls.
With regard to the DRl 3 haplotypes (overall RR of0.79 for adult patients), DQA and DQB genotyping allow to differentiate the DRB1*1301-DQBl *0603-DQAl *0103 and the DRB 1*1 302-DQB 1 *0604-DQAI *0102 haplotypes (34) . The latter has been reported to be associated with IDDM, whereas it was neutral in our study in both groups of diabetic patients, contrasting with a protective effect ofthe former (RR = 0.24, PC < 0.005). Finally, the DR7 haplotype was found to be protective only in childhood-onset diabetic patients (RR = 0.21, P, < 0.005).
Role ofresidue 5 7 ofthe DQ3 chain
The presence at position 57 of the outer domain of the DQ,3 chain of either charged (Asp) or neutral (Val, Ser, or Ala) residues has been investigated (11) . 64% of the adult-onset patients were homozygous for the absence ofAsp at position 57 versus 72% of the pediatric group and 26% of the healthy controls (Table VII) . This figure, particularly in the adult group, is significantly lower than in previous studies, most of which mainly included children. An age-dependent gradient similar to that for the prevalence of DR3/DR4 was also found for the presence of at least one Asp residue at position 57 (30% of the diabetic children, 32% of the adults < 30 yr, 45% of those >30 yr, and 74% of the controls). Homozygosity for Asp-positive alleles was lower in the diabetic children (5%) than in the older adults (12%) and controls (26%). All the Asp/Asp homozygous patients (adults and children) were non-DR3/non-DR4, although all the non-DR3/non-DR4 children were Asp/Asp homozygotes compared with only 23% of the non-DR3/non-DR4 adult patients. Among the DQB1 alleles with a non-Asp residue 57, only DQB1 *0302 and 0201 (both with Ala) were associated with adult-onset IDDM. The DQB 1 *0201 allele was probably not solely responsible for IDDM susceptibility since it was associated with either the DR7 (protective) or DR3 (risk) haplotype. DQB 1 *0502 and 0604 did not confer significant susceptibility; indeed, DQB 1*0501 was associated with a protective effect. Three DQB 1 alleles carrying an Asp at position 57 were associated with a protective effect (DQB 1*0602, 0603, and 0301) . The protection confered by DQB 1 *0503,0601, or 0303 alleles did not reach statistical significance. Lastly, the DQB 1 *0402 allele was neutral.
DQA locus
In all the IDDM and control subjects studied, the DQA alleles strictly matched those expected on the basis ofthe known linkage disequilibria between the DRB, DQB, and DQA subregions. Therefore, the increased DQA 1 *0301 and DQA 1 *0501 frequencies in the IDDM patients was directly related to that of DRB 1 *04-DQB 1 *0302 and DRB I *03-DQB 1 *0201 haplotypes, respectively. Similarly, the decrease in DQA 1*0103 was directly associated with that ofthe DRB1 * 13-DQB1 *0603 haplotype. In particular, the frequency ofthe Arg residue in position 52 of the DQa chain, which has recently been incriminated in IDDM susceptibility (35) , was directly linked to that of the DR3 and/or DR4 IDDM susceptibility alleles. All the diabetic patients and healthy controls with non-Asp residues at DQ,3 57 and Arg residues at DQa 52 were DR3 or DR4 homozygotes or DR3/4 heterozygotes.
It thus appears that DQA oligotyping in Caucasians does not itself improve the predictive value of risk determination in terms ofprotection or susceptibility to disease, even when combined with an Asp at position 57 of the DQ3 chain.
Clinical and immunological correlations Because of the marked genetic differences between the adult and child diabetics, who all presented as type 1 IDDM, 190 adult-onset patients included in a Cs-A therapeutic trial were analyzed in particular detail according to their genotype (Table  VIII) . All presented with recent weight loss, polyuria, and ketosis or ketoacidosis. The mean age at onset, duration of clinical symptoms, initial glucose blood level, and insulin needs were not significantly different in non-DR3 / non-DR4 from those in DR3 and/or DR4 patients. A tendency towards a less frequent family history of IDDM and a more frequent family history of NIDDM was found in non-DR3 / non-DR4 patients in comparison to patients carrying other genotypes, but the differences were not statistically significant. The degree of weight loss was also less marked in these patients. Furthermore, the frequency of ICA was considerably lower (20 vs. 64.7% in the DR3 and/ or DR4 patients and 69% in the diabetic children, Pc < 0.0001) Like the childhood-onset diabetics, the adult-onset IDDM patients showed a significantly higher frequency of DR3 and DR4 haplotypes, as well as a lower frequency of DR2, DR7, and DR1 3 (protective) haplotypes. However, the frequency of DR3 and/or DR4 patients, particularly in the DR3 /4 heterozygous combination, was significantly lower and that of non-DR3 / non-DR4 patients significantly higher in the adult-than in childhood-onset patients. These two trends were already apparent in the 15-30-yr age group and even more marked in the group aged >30 yr.
The risk associated with a combination ofthe two transallelic markers exceeded that of homozygosity for DR4 but was similar to that in patients homozygous for DR3. This observation strongly argues in favor of a synergistic effect between independent susceptibility alleles and confirms the special permissive role of DR3. The highly predisposing influence of the DR3/4 genotype is also indicated by the highest rate ofdisease concordance in DR3/4 sibling pairs and monozygotic twins (39) . It can be assumed in such patients that strong predisposing immunological factors linked to the DR3 and DR4 haplotypes trigger the disease early in life, explaining the predominance of DR3/4 patients in the childhood-onset group (40) . Conversely, IDDM would be more heterogeneous in adults than in children, as in this study, probably because in the absence ofthe strongly penetrant DR3/4 genotype the HLA contribution is more diluted by the effect of other genes and by environmental or other acquired factors.
The analysis of class II alleles confirms this age-dependent susceptibility gradient. Restriction fragment length polymorphism and oligotyping studies have focused on the responsibility of the DQB locus in IDDM predisposition. The DQB 1*0602 and 0603 alleles have been assumed to be involved in protection against diabetes, whereas DQB1 *0302 is considered the major candidate susceptibility gene. Our findings confirmed these data in both age groups with, however, a lower frequency of DQB 1*0302 and a higher frequency of DQB 1 *0602 and 0603 in adult-onset than in childhood-onset IDDM patients. Furthermore, mapping ofprotective or susceptibility genes to the DQB locus rather than to the DRB locus was not apparent from our data. First, the DQB1 *0302 gene was present in only 46.5% of these Caucasian patients versus 11.6% of healthy individuals. Second, among the DR4-DQB 1 *0302 haplotypes, susceptibility to IDDM varied considerably and only DRB 1*0402 and DRB 1*0405 were closely associated with the disease. This observation, which contrasts with most previous findings, was made in both patient age groups. DR4 subtypes differ at positions 67-71 of the outer domain of the DRB chain. This region, which has been implicated in susceptibility to rheumatoid arthritis and pemphigus vulgaris (6, 41, 42) could thus also play a role in IDDM. Finally, even if it is likely that the DQB locus participates in disease onset in DR4-positive haplotypes, this is probably not the case for non-DR4 haplotypes: the same DQB1 *0201 allele was found on the susceptible DR3 haplotype and on the protective DR7 haplotype. Thus, any other gene on the DR3 haplotype is a potential susceptibility candidate.
Another interesting approach to the predisposing class II alleles has been to search for predisposition residues on DQa and DQB chains. The presence of a negatively charged residue at position 57 of the DQB chain has thus been reported to confer resistance to disease, whereas a neutral residue is thought to be permissive. We confirmed that Asp residue 57 is less common in childhood-and adult-onset IDDM than in healthy controls, although the difference was more clearcut in the children. Up to 36 (43) (44) (45) (46) .
The genetic contribution of the DQA locus in Caucasians may be interpreted in this sense, rather than by considering it as a primary susceptibility determinant. In our study, DQA alleles did not confer a greater risk than DQB, with which it shows strong linkage disequilibrium. The presence of two Arg residues at position 52 of the DQa chain and non-Asp residues at position 57 of the DQJ3 chain in IDDM patients (35) could thus be exclusively related to the linkage disequilibrium with DR3 and/or DR4 alleles. We found that only 32% of the IDDM patients possessed the four susceptibility molecules, all being DR3/4 heterozygotes or DR3/3 or DR4/4 homozygotes. The DQA contribution is probably different in non-Caucasoid populations, as suggested in Japanese (47) or in Black (48) subjects in whom a particular DQa,,3 heterodimer, coded either in cis or in trans position, seems to be involved in disease predisposition.
A high frequency of non-DR3/non-DR4 in adult-onset IDDM patients has already been reported in smaller series of patients studied by means ofserological HLA-DR typing (49) . It was very clearcut in this large study, particularly in patients with onset after the age of 30 yr. These non-DR3/non-DR4 patients showed other peculiarities, with a notably low incidence of ICA and less severe disease at onset, raising doubts as to the autoimmune origin in at least some of these patients.
Our data confirm the genetic heterogeneity of patients who present unambiguously with clinical symptoms typical of IDDM and point to a need for complete patient characterization (including accurate HLA typing), particularly in epidemiological or therapeutic studies. They also suggest the existence of other mechanisms in atypical cases (non-DR3/non-DR4 or Asp/Asp patients), as previously done in young black American diabetics (38) and patients with acute necrosis of # cells (50) . Caution should be used when single HLA markers are employed to predict or exclude the risk for diabetes. In fact, the relative risks show that there are not only one or two predisposing alleles but a whole spectrum ofpredisposing and protective alleles associated with different relative risks according to age of disease onset.
In closing, it appears that several factors are probably required to trigger IDDM, possibly including relevant sequences in other loci than DR and DQ (5 1 ). Preliminary reports have shown some linkage disequilibrium with DP in certain haplotypes (52). Alternatively, quantitative variations in the expression of class II genes, controlled at the level of regulatory segments, could be critical in determining the incidence of IDDM in individuals genetically at risk (53) . Non-MHC genes probably play an important role, as recently found in the nonobese diabetic mouse (54, 55) .
